“The study in first-line triple-negative breast cancer is expected to begin later this year.”

In context

“c pulmonary fibrosis is expected next year. And we're also expecting to see MRD negativity data in-house later this year and PFS data next year from the Phase III EXCALIBER study of iberdomide. This could provide additional validation of our CEL MoD platform as a next-generation potential standard of care in multiple myeloma. In terms of life cycle management, we now have several ongoing registrational trials for Cobenfy in Alzheimer's disease patients. These include studies in Alzheimer's psychosis, agitation and cognition impairment. In addition, we are also enrolling a Phase III study in bipolar 1 disorder. In addition, we have attractive opportunities to invest in numerous oncology pivotal trials. BNT327 is enrolling in first-line non-small cell lung cancer and small cell lung cancer. The study in first-line triple-negative breast cancer is expected to begin later this year. We're also advancing next-generation platforms that could redefine their respective categories. We are initiating 2 registrational studies for our PRMT5 inhibitor, one in non-small cell lung cancer and another in pancreatic cancer based on encouraging early data with additional longer-term non-small cell lung cancer results to be presented at World Lung. Additionally, we are now recruiting a pivotal study for our EGFR HER3 targeting ADC Iza-bren in first-line triple-negative breast cancer and expect early data in non-small cell lung cancer and other solid tumors later this year. Lastly, in immunology, we are also now enrolling patients in a pivotal Phase II study for our CD19 NEX-T cell therapy in severe refractory lupus. Data readouts are expected to continue next year and throughout the”